Philippe Saas

Dr. Philippe Saas

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2007 in Stem Cells
Verified
Journal Article
Closed access
PDF file
ZSZohair Selmani
Zohair Selmani
ANAbderrahim Naji
Abderrahim Naji
IZInes Zidi
Ines Zidi
BFBenoit Favier
Benoit Favier
EGEmilie Gaiffe
Emilie Gaiffe
FDFrederic Deschaseaux
Frederic Deschaseaux
Adult bone marrow-derived mesenchymal stem cells (MSCs) are multipotent cells that are the subject of intense investigation in regenerative medicine. In addition, MSCs possess immunomodulatory properties with therapeutic potential to prevent graft-versus-host disease (GvHD) in allogeneic hematopoietic cell transplantation. Indeed, MSCs can inhibit natural killer (NK) function, modulate dendritic cell maturation, and suppress allogeneic T-cell response. Here, we report that the nonclassic human leukocyte antigen (HLA) class I molecule HLA-G is responsible for the immunomodulatory properties of MSCs. Our data show that MSCs secrete the soluble isoform HLA-G5 and that such secretion is interleukin-10-dependent. Moreover, cell contact between MSCs and allostimulated T cells is required to obtain a full HLA-G5 secretion and, as consequence, a full immunomodulation from MSCs. Blocking experiments using neutralizing anti-HLA-G antibody demonstrate that HLA-G5 contributes first to the suppression of allogeneic T-cell proliferation and then to the expansion of CD4+CD25highFOXP3+ regulatory T cells. Furthermore, we demonstrate that in addition to their action on the adaptive immune system, MSCs, through HLA-G5, affect innate immunity by inhibiting both NK cell-mediated cytolysis and interferon-γ secretion. Our results provide evidence that HLA-G5 secreted by MSCs is critical to the suppressive functions of MSCs and should contribute to improving clinical therapeutic trials that use MSCs to prevent GvHD.Disclosure of potential conflicts of interest is found at the end of this article.

15 March 1997 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PSPhilippe Saas
Philippe Saas
PWP R Walker
P R Walker
MHM Hahne
M Hahne
AQA L Quiquerez
A L Quiquerez
VSV Schnuriger
V Schnuriger
PDP Y Dietrich
P Y Dietrich
Astrocytomas are among the most common brain tumors that are usually fatal in their malignant form. They appear to progress without significant impedance from the immune system, despite the presence of intratumoral T cell infiltration. To date, this has been thought to be the result of T cell immunosuppression induced by astrocytoma-derived cytokines. Here, we propose that cell contact-mediated events also play a role, since we demonstrate the in vivo expression of Fas ligand (FasL/CD95L) by human astrocytoma and the efficient killing of Fas-bearing cells by astrocytoma lines in vitro and by tumor cells ex vivo. Functional FasL is expressed by human, mouse, and rat astrocytoma and hence may be a general feature of this nonlymphoid tumor. In the brain, astrocytoma cells can potentially deliver a death signal to Fas+ cells which include infiltrating leukocytes and, paradoxically, astrocytoma cells themselves. The expression of FasL by astrocytoma cells may extend the processes that are postulated to occur in normal brain to maintain immune privilege, since we also show FasL expression by neurons. Overall, our findings suggest that FasL-induced apoptosis by astrocytoma cells may play a significant role in both immunosuppression and the regulation of tumor growth within the central nervous system.

27 April 2008 in Nature Medicine
Verified
Journal Article
Closed access
SPSylvain Perruche
Sylvain Perruche
PZPin Zhang
Pin Zhang
YLYongzhong Liu
Yongzhong Liu
PSPhilippe Saas
Philippe Saas
JBJeffrey A Bluestone
Jeffrey A Bluestone
WCWanJun Chen
WanJun Chen

25 July 2012 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MSMaxime Samson
Maxime Samson
SASylvain Audia
Sylvain Audia
JFJennifer Fraszczak
Jennifer Fraszczak
MTMalika Trad
Malika Trad
POPaul Ornetti
Paul Ornetti
BBBernard Bonnotte
Bernard Bonnotte
Objective: Giant cell arteritis (GCA) is the most frequently occurring vasculitis in elderly individuals, and its pathogenesis is not fully understood. The objective of this study was to decipher the role of the major CD4+ T cell subsets in GCA and its rheumatologic form, polymyalgia rheumatica (PMR).Methods: A prospective study of the phenotype and the function of major CD4+ T cell subsets (Th1, Th17, and Treg cells) was performed in 34 untreated patients with GCA or PMR, in comparison with 31 healthy control subjects and with the 27 treated patients who remained after the 7 others withdrew.Results: Compared with control subjects, patients with GCA and patients with PMR had a decreased frequency of Treg cells and Th1 cells, whereas the percentage of Th17 cells was significantly increased. Furthermore, an analysis of temporal artery biopsy specimens obtained from patients affected by GCA for whom biopsy results were positive demonstrated massive infiltration by Th17 and Th1 lymphocytes without any Treg cells. After glucocorticoid treatment, the percentages of circulating Th1 and Th17 cells decreased, whereas no change in the Treg cell frequency was observed. The frequency of CD161+CD4+ T cells, which are considered to be Th17 cell precursors, was similar in patients and control subjects. However, these cells highly infiltrated GCA temporal artery biopsy specimens, and their ability to produce interleukin‐17 in vitro was significantly enhanced in patients with GCA and patients with PMR and was correlated with a decrease in the phosphorylated form of STAT‐1.Conclusion: This study is the first to demonstrate that the frequency of Treg cells is decreased in patients with GCA and patients with PMR, and that CD161+CD4+ T lymphocytes, differentiated into Th1 cells and Th17 cells, are involved in the pathogenesis of GCA and PMR.

15 May 1997 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
PWP R Walker
P R Walker
PSPhilippe Saas
Philippe Saas
PDP Y Dietrich
P Y Dietrich
Several different tumor types have recently been shown to express functional Fas ligand (FasL), which may represent an additional mechanism of tumor escape. However, the in vivo significance of these findings in the context of potent adversaries such as activated CTL or NK cells remains to be fully established. The potential interactions between tumor cells and the host immune response are thus more complex than previously thought; their elucidation will benefit the rational design of cancer immunotherapy strategies.

1 February 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
ALAnna Lluis
Anna Lluis
MDMartin Depner
Martin Depner
BGBeatrice Gaugler
Beatrice Gaugler
PSPhilippe Saas
Philippe Saas
VCVera Isabel Casaca
Vera Isabel Casaca
GDG. Doekes
G. Doekes